Enhanced RP-HPLC method for Simultaneous Quantification of Five Pharmacologically Different Active Pharmaceutical Ingredients


Harish Bhandarkar1, Pralhad Rege2* and Vijaykumar Chavan1

1Department of chemistry, Ramnarain Ruia Autonomous College, Mumbai, Maharashtra, India.

2Department of chemistry, St. Xavier’s College, Mumbai, Maharashtra, India.

Corresponding Author E-mail: harishb1983@yahoo.com

Download this article as: 

ABSTRACT:

This research primarily focuses on newly developed method by reverse phase high performance liquid chromatography (RP-HPLC) for quantification and simultaneous estimation for five different active pharmaceutical ingredients (APIs) with different pharmacological activities like antihistamine, anticlotting, antiretroviral, iron chelators and antihypertensive. The method effectively separates five different APIs in single gradient method with reduction run time thereby minimizing solvent consumption and waste generation. Chromatographic separation was achieved using Inertsil ODS-3V C18 (5.0 µm), length 250mm, ID 4.6 mm column with eluent of phosphoric acid (0.1%) (A) and acetonitrile (B) using gradient program at 1.0 ml/min flow rate. Five APIs were well separated and quantified at wavelength 254 nm with column temperature controlled at 35°C. The method validation was performed with specificity, precision, accuracy, robustness, ruggedness and solution stability found within acceptable limits. (98% to 102%) Linearity for all five APIs showed appreciable correlation relationship more than 0.999, confirming the method reliability across the working range. The validated method provides significant role in sustainable pharmaceutical analysis with a robust analytical tool for regulatory submissions, quality control release and commercial batch testing throughout the APIs manufacturing processes. The method simplicity, accuracy and minimal waste generation make it highly valuable for continuous production monitoring, quality assurance and regulatory submission in pharmaceutical operations.

KEYWORDS:

API; Assay; Method development; Quantification; Validation

Introduction 

The growing demand for antihistamines, anticlotting, antiretroviral, iron chelators and antihypertensive drugs due to increased R&D investments and market growth, analytical methodology has gained importance. Determination of API play important role in pharmaceutical reliability, safety and efficacy of drug administration to patients. Assay analysis plays a crucial role in synthesis and quality check. The mass balance of compounds can be achieved by quantification of API analysis. Several active pharmaceutical ingredients such as Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox with different pharmacological activities has been explored1-5. Several assay methods have been established to evaluate the combination of two pharmaceutical agents. Existing analytical methods in the literature are largely confine to simultaneous assay of two or more drugs belonging to a single therapeutic class including antimalarial, antihypertensive, antidiabetic etc. Simultaneous quantification of diverse pharmacological activities APIs provides reduction in analysis time, solvent consumption and reduce cost. A single method for five APIs assay quantification overcomes the traditional methods involve separate chromatographic runs for individual API generating large volume of organic solvent waste and time consuming. Furthermore, application of newly developed assay method can be applied to formulation dosage form and biological matrices. The method focuses on minimizing waste generation to supports quality control testing, stability studies and product lifecycle management.6 However an RP-HPLC method for quantification of five different active pharmaceutical ingredients with different pharmacological activities has not been established. Literature review revealed different analytical methodologies for assay quantification like HPTLC, UV-spectrophotometry, HPLC & HPLC-MS has been put forward for Bilastine7-8, Lercanidipine9-10, Rivaroxaban11, Dolutegravir12 and Deferasirox13. Among these techniques, RP-HPLC method is accurate, simple and consistent technique for ease of quantification with reproducible results14-23. Initially isocratic method for separation of five APIs using RP-HPLC was analyzed using Zorbax Agilent C-18 column with mobile phase (phosphate buffer: acetonitrile) (65:35 v/v) was performed. But isocratic method failed to achieve effective resolution between different APIs. However, method was modified with gradient composition using ortho-phosphoric acid and acetonitrile as eluent A and eluent B respectively with Inertsil C-18 column was employed. The optimized method successfully resolved the five different APIs with well resolved peaks. Method validation was performed, evaluating specificity, linearity, accuracy, method precision, ruggedness, robustness, and solution stability.

Materials and Methods

Instruments

The results from the development and validation of the HPLC method were analysed using Agilent Technologies 1260 Infinity-II system, equipped with Photodiode array (PDA) detector. Data processing and quantification of assay results for five actives pharmaceutical ingredients (API) were carried out using Agilent Open LAB data analysis software. (build version 2.203.3.59)

Solvents and reagents

In preparing of mobile phase the solvent system used to carry through the sample through chromatographic column, high purity water was utilized. This water was obtained using Millipore water purification system, ensures removal of impurities, ions and contaminates that could interfere with chromatographic separation and detection process. For chromatographic testing and analysis, two key chemical reagents ortho phosphoric acid and acetonitrile were procured from Merck. These reagents were selected to ensure the reliability and reproducibility of analytical results.  For the method development and validation studies, working standard of Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine were procured from BLD Pharmatech Ltd. (India) These working standard serves as reference material to establish and validate the analytical method, ensuring quantification of each compound with and specificity and precision.

Preparation of solutions

Preparation of diluent

Water: Acetonitrile 20:80 (v/v) use as diluent.

Standard preparation

Weighed accurately about 50 mg each of Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine working standards to volumetric flask 25 ml. Sonicate to dissolve for preparing 2000 µg/mL stock solution. Further dilute 1.0 ml to 20 ml (100 µg/mL) to obtain the working standard solution. Filter and inject.

Test preparation

Test samples were prepared by weighing 50 mg to 25 mL volumetric flask, adding approximately 15 ml of diluent, sonicating for 5-10 minutes, cooling, and diluting to volume. Further dilute 1.0 ml to 20 ml with diluent to obtain test solution. (100 µg/mL) If the solution is unclear then filter and inject.

Preparation of linearity solutions

Weighed accurately about 50 mg each of Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine to volumetric flask 25 ml. Sonicate to dissolve for preparing 2000 µg/mL linearity stock solution (A). From stock solution A pipetted out 0.5 ml (50 µg/mL),0.8 ml (80 µg/mL),1.0 ml (100 µg/mL),1.2 ml (120 µg/mL) and 1.5 ml (150 µg/mL) transferred to different 20 ml volumetric flask and dilute up to the mark with diluent. Filter and inject in triplicate for each level.

Preparation of accuracy solutions at 80%, 100% and 120 %:

Test spike preparation: (80%)

Weigh accurately 40.0 ± 5.0 mg of sample transferred to volumetric flask 25 ml. Sonicate to dissolve. Further diluted 1.0 ml to 20 ml with diluent. Inject in triplicate.

Test spike preparation: (100%)

Weigh accurately 50.0 ± 5.0 mg of sample transported to volumetric flask 25 ml. Sonicate to dissolve. Diluted 1.0 ml to 20 ml with diluent. Inject in triplicate.

Test spike preparation: (120%)

Weigh accurately 60.0 ± 5.0 mg of sample in volumetric flask 25 ml. Sonicate to dissolve. Diluted from 1.0 ml to 20 ml with diluent. Inject in triplicate.

Preparation of Method Precision and Intermediate Precision (Ruggedness) solutions

Weighed accurately six individual sample preparation about 50 mg each and transferred to volumetric flask 25 ml. Sonicate to dissolve for preparing 2000 µg/mL stock solutions. Further dilute 1.0 ml to 20 ml (100 µg/mL) to obtain the sample solution. Filter and inject. % RSD found to be less than 2%.

Robustness

Robustness was conducted on different composition of mobile phase, column flow rate and temperature. The sample concentration (100 µg/mL) was prepared and analysed on different mobile phase composition ±10% (0.1%), flow rate 0.9 ml/min and 1.1 ml/min, column temperature 30°C and 40°C. % Assay Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox were determined to be within the range 98% to 102 %.

Solution Stability

Solution Stability was assessed at different time intervals initial, 12 hrs and 24 hrs for sample concentration (100 µg/mL). % Assay Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox were determined to be within the range 98% to 102 %.

Chromatographic Conditions

All chromatographic analyses were conducted using high-performance liquid chromatography (HPLC) system (Agilent Technologies 1260 Infinity II, USA). Separation of all analytes was achieved on Inertsil 3V C18 analytical column (5.0 µmx4.6 mm x 250 mm; Part no. 23B0394504). A gradient elution program was employed, utilizing orthophosphoric acid (85%) as buffer component and acetonitrile as organic modifier. The mobile phase was delivered at constant flow rate of 1.0 ml/min. Ultraviolet photodiode array (PDA) detection was performed at 254 nm for quantification and column oven temperature was operated at 35°C throughout the analysis.

Results

Characterization of Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine.

Different sophisticated analytical instruments were used for the characterization before proceeding for method development and validation. These included:

  • Fourier Transform Infrared Spectroscopy (FTIR) by Bruker (Identification of functional groups)
  • Reverse phase High Performance Liquid Chromatography (RP-HPLC) by Agilent (%Purity APIs)
  • Liquid Chromatography-Mass Spectroscopy (LCMS) by Agilent (Mass identification)
  • Thermal Gravimetric Analysis (TGA) by Perkin Elmer (Inorganic residue content)
  • Differential Scanning Calorimetry (DSC) by Perkin Elmer (Melting point and thermal analysis)
  • Finally, the characterized active pharmaceutical ingredients (APIs) along with respective IUPAC name in Table-1
Table 1: Characterized active pharmaceutical ingredients (APIs) along with respective IUPAC name

Click here to View Table

Column selection and separation

Among the solvents evaluated, acetonitrile: water (80:20) v/v selected for this study demonstrated excellent solubilizing capacity for all five compounds like Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine producing strong response with well-defined symmetrical peak shapes. Based on these outcomes, mixture of acetonitrile: water (80:20) v/v was considered as diluent throughout the research study. To identify the most suitable stationary phase for chromatographic separation, different columns were screened like Eclipse zorbax, Waters acquity, Koramsil and Inertsil. After evaluation Inertsil C-18-3V column was selected for better separation and good detector response. A key advantage of this column lies in its advanced end-capping technology, effectively neutralizes residual silanol groups on silica surface, thereby minimizing peak tailing and improving overall chromatographic performance. The column temperature was operated at 35°C to avoid shift in retention time. Separation was achieved using gradient composition of ortho-phosphoric acid (buffer as A) and acetonitrile (organic modifier as B) at column flow rate 1.0 ml/min. Under optimized chromatographic conditions, five analytes eluted in following order with their corresponding retention times: Bilastine (8.1mins), Lercanidipine (11.8 mins), Rivaroxaban (12.8 mins), Dolutegravir (14.1mins), and Deferasirox (18.0 mins). The chromatographic system demonstrated excellent performance, with all peaks showing tailing factor (≥ 2.0), theoretical plates more the 2000 and resolution between Bilastine and Lercanidipine (≥ 2.0). These results collectively confirm that the developed method meets all acceptance criteria as presented in (Figure:1).

Figure 1: System suitability HPLC chromatogram for Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine.

Click here to View Figure

Optimization of HPLC parameters

Accurate quantification using HPLC methodology is fundamental to ensuring the purity and quality assessment of active pharmaceutical ingredients (API). In initial phase of method development, relatively straightforward and widely accessible analytical techniques such as UV-Visible spectrophotometry, TLC and HPTLC were explored and evaluated. However, despite their simplicity and routine applicability these techniques proved inadequate in delivering precise quantification of five targeted compounds like Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine.To overcome the limitations, more advanced and sensitive detection technique was employed. High performance liquid chromatography with photodiode array (PDA) detection technique was explored during early method development stages. This technique demonstrated a significant and consistent detector response at 254 nm, suitable for simultaneous quantification of all five APIs. Based upon these findings, the chromatographic conditions were further optimized to achieve precise and reproducible quantification of Bilastine, Rivaroxaban, Dolutegravir, Deferasirox and Lercanidipine. (Table 2).

Table 2: Optimized HPLC chromatographic condition

Equipment

 Agilent 1260 Infinity-II HPLC

Column Dimensions

Inertsil 3V ODS C18 (5.0 µm x250 mm x 4.6 mm) (S/N 23B0394504)
Wavelength

254 ± 4 nm

Flow

1 ml/min (Gradient flow).
Column temperature

35±2°C

Injector volume

10 µl
Gradient run time

25 mins

Eluent A

0.1 % orthophosphoric acid in water (v/v)
Eluent B

 Acetonitrile (100%)

Diluent

Acetonitrile: Water (80:20) (v/v)
Gradient program:

Time (mins)

% Eluent A % Eluent B Column flow rate (ml/min)
0 .01 85 15

1.0

2.0

85 15 1.0
5.0 65 35

1.0

15.0

25 75 1.0
20.0 25 75

1.0

21.1

85 15 1.0
25.0 85 15

1.0

Method validation

Newly developed HPLC method followed by validation parameters like specificity, linearity, accuracy, method precision, ruggedness and robustness. This validation process established the methods suitability and reliability for its intended analytical application.

Specificity

Bilastine, Lercanidipine Rivaroxaban, Dolutegravir and Deferasirox peaks were well resolved, without any interference at respective retention time. Six times system suitability solution was analysed at 100 µg/mL to check %RSD ≥ 2.0. Summarized in Table 3 & Table 4 as given below:

Table 3: Five distinct active pharmaceutical ingredients were characterized by different retention time.

Name

Retention time (mins)
Bilastine

8.1

Lercanidipine

11.8
Rivaroxaban

12.8

Dolutegravir

14.1
Deferasirox

18.0

Table 4: System suitability solution for five different APIs with relative standard deviation values.

System suitability

% Bilastine % Lercanidipine % Rivaroxaban % Dolutegravir % Deferasirox
Test spike 100 % 1-1 611 1139 2791 3055

3572

Test spike 100 % 1-2

614 1143 2802 3066 3585
Test spike 100 % 1-3 614 1144 2801 3067

3586

Test spike 100 % 1-4

614 1143 2801 3067 3586
Test spike 100 % 1-5 612 1154 2794 3059

3577

Test spike 100 % 1-6

612 1141 2795 3061 3578
Mean 613 1144 2797 3063

3581

SD

1.2 5.3 4.4 5.0 5.7
% RSD 0.2 0.5 0.2 0.2

0.2

Linearity

The analytical method demonstrated appreciable linearity for Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox through five-point calibration curve between concentrations from 50 to 150 µg/mL. Linear regression curves yielded slope, intercept, and correlation coefficient value greater than 0.999. Mentioned in Table 5-9.

Table 5: Linearity levels of Bilastine

Linearity Level

Injection-1 Injection-2 Injection-3 Average
50.2 295.6 295.6 295.6

295.6

80.3

469.6 470.5 470.4 470.2
100.4 606.6 606.8 606.7

606.7

120.5

731.1 731.9 731.6 731.5
150.6 918.7 913.1 913.5

915.1

 

Figure 2: Linearity curve for Bilastine

Click here to View Figure

Table 6: Linearity levels of Lercanidipine

Linearity Level

Injection-1 Injection-2 Injection-3 Average
50.9 556.7 556.4 557.3

556.8

81.4

906.9 920.1 920.3 915.8
101.8 1142.5 1142.4 1130.5

1138.5

122.2

1378.8 1378.2 1381.4 1379.5
152.7 1678.1 1672.1 1671.5

1673.9

 

Figure 3: Linearity curve for Lercanidipine

Click here to View Figure

 Table 7: Linearity levels of Rivaroxaban

Linearity Level

Injection-1 Injection-2 Injection-3 Average
49.9 1347.9 1345.6 1346.7

1346.7

79.8

2246.5 2249.9 2250.1 2248.8
99.8 2759.8 2760.8 2764.1

2761.6

119.8

3326.8 3327.5 3333.1 3329.1
149.7 4166.3 4138.4 4137.2

4147.3

 

Figure 4: Linearity curve for Rivaroxaban

Click here to View Figure

Table 8: Linearity levels of Dolutegravir

Linearity Level

Injection-1 Injection-2 Injection-3 Average

50.4

1489.4 1487.9 1489.3

1488.9

80.6 2454.1 2457.6 2458.7

2456.8

100.8

3027.1 3028.1 3033.2 3029.5
121.0 3664.2 3665.1 3670.4

3666.6

151.2

4591.5 4562.6 4561.8

4572.0

 

Figure 5: Linearity curve for Dolutegravir 

Click here to View Figure

Table 9: Linearity levels of Deferasirox

Linearity Level

Injection-1 Injection-2 Injection-3 Average
50.7 1736.9 1734.2 1735.3

1735.5

81.1

2865.9 2869.4 2458.7 2731.3
101.4 3534.1 3535.1 3540.3

3536.5

121.7

4280.7 4281.1 4286.8 4282.9
152.1 5335.1 5320.9 5320.4

5325.5

 

Figure 6: Linearity curve for Deferasirox

Click here to View Figure

Accuracy

Accuracy was performed at 80%, 100% and 120% levels in triplicate to obtain recovery between 98 % to    102 % for Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox. Mentioned in Table 10-14.

Table 10: Accuracy of Bilastine

Accuracy at 80 % Level                        

Amount added Amount found % Recovery Mean
474.1 79.8 79.7

99.8

99.7

473.7

79.8 79.3 99.3
472.8 79.8 80.0

100.2

Accuracy at 100 % Level                       

Amount added Amount found % Recovery Mean
613.1 99.4 100.3

100.9

100.2

613.8

99.4 99.2 99.8
614.1 99.4 99.5

100.1

Accuracy at 120 % Level                        

Amount added Amount found % Recovery Mean
738.3 119.8 120.7

100.8

101.3

737.4

119.8 121.4 101.4
739.1 119.8 121.9

101.8

Table 11: Accuracy of Lercanidipine

Accuracy at 80 % Level                        

Amount added Amount found % Recovery Mean
929.6 79.8 79.8

100.0

99.8

928.8

79.8 79.7 99.9
927.1 79.8 79.6

99.7

Accuracy at 100 % Level                         

Amount added Amount found % Recovery Mean
1144.3 99.4 101.0

101.6

100.2

1159.1

99.4 98.7 99.3
1158.8 99.4 99.1

99.7

Accuracy at 120 % Level                         

Amount added Amount found % Recovery Mean
1393.6 119.8 119.2

99.5

100.5

1392.1

119.8 121.6 101.6
1392.5 119.8 120.2

100.4

Table 12: Accuracy of Rivaroxaban

Accuracy at 80 % Level                        

Amount added Amount found % Recovery Mean
2273.0 79.8 79.6

99.7

99.9

2272.0

79.8 79.0 99.0
2266.0 79.8 80.7

101.1

Accuracy at 100 % Level     

Amount added Amount found % Recovery Mean
2804.0 99.4 99.9

100.5

100.1

2803.0

99.4 99.0 99.6
2802.0 99.4 99.4

100.0

Accuracy at 120 % Level                         

Amount added Amount found % Recovery Mean
3364.0 119.8 120.2

100.3

99.7

3359.0

119.8 118.9 99.3
3366.0 119.8 119.1

99.5

Table 13: Accuracy of Dolutegravir

Accuracy at 80 % Level                        

Amount added Amount found % Recovery Mean
2481 79.8 79.8

99.9

99.2

2479

79.8 78.9 98.8
2475 79.8 79.0

99.0

Accuracy at 100 % Level                        

Amount added Amount found % Recovery Mean
3069.0 99.4 100.0

100.6

100.0

3069.0

99.4 99.0 99.6
3070.0 99.4 99.4

100.0

Accuracy at 120 % Level                         

Amount added Amount found % Recovery Mean
3691.0 119.8 120.6

100.7

100.1

3687.0

119.8 118.7 99.1
3697.0 119.8 120.2

100.4

Table 14: Accuracy of Deferasirox

Accuracy at 80 % Level                        

Amount added Amount found % Recovery Mean
2904 79.8 79.3

99.3

99.7

2902

79.8 79.8 100.0
2897 79.8 79.7

99.8

Accuracy at 100 % Level                       

Amount added Amount found % Recovery Mean
3592 99.4 99.9

100.5

100.0

3589

99.4 99.0 99.6
3588 99.4 99.4

100.0

Accuracy at 120 % Level                    

Amount added Amount found % Recovery Mean
4324 119.8 120.8

100.9

100.8

4319

119.8 120.1 100.3
4326 119.8 121.1

101.2

Method Precision

Analysing six different preparations of sample solution at 100 % (100 µg/ml) were analysed for method precision. Resulting % RSD for Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox were 0.3,0.4,0.8,0.7 & 0.5 respectively. Mentioned in Table 15.

Table 15: Method precision

Method Precision

% Bilastine % Lercanidipine % Rivaroxaban % Dolutegravir % Deferasirox
Test spike 100 % 1-1 99.4 99.6 99.2 99.4

99.2

Test spike 100 % 1-2

98.8 100.3 101.0 100.6 100.3
Test spike 100 % 1-3 99.4 99.6 99.6 98.6

99.5

Test spike 100 % 1-4

99.5 100.0 99.1 99.9 99.7
Test spike 100 % 1-5 98.7 99.1 98.7 99.0

98.7

Test spike 100 % 1-6

99.3 99.5 99.0 99.4 99.1
Mean 99.2 99.7 99.4 99.5

99.4

SD

0.3 0.4 0.8 0.6 0.5
% RSD 0.3 0.4 0.8 0.7

0.5

Intermediate Precision (Ruggedness)

Analysing six different preparations of sample solution at 100 % (100 µg/ml) across different instruments, different analysts and different days. Resulting % RSD for Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox were 0.2,0.4,0.2,0.2 & 0.2 respectively. Mentioned in Table 16.

Table 16: Intermediate Precision

Method Precision

% Bilastine % Lercanidipine % Rivaroxaban % Dolutegravir % Deferasirox
Test spike 100 % 1-1 99.6 98.6 99.6 99.7

99.6

Test spike 100 % 1-2

99.8 100.1 99.8 99.9 99.9
Test spike 100 % 1-3 99.2 99.4 99.2 99.3

99.2

Test spike 100 % 1-4

99.6 99.7 99.5 99.6 99.6
Test spike 100 % 1-5 99.6 99.6 99.5 99.6

99.5

Test spike 100 % 1-6

99.2 99.5 99.3 99.2 99.3
Mean 99.5 99.5 99.5 99.5

99.5

SD

0.22 0.4 0.2 0.2 0.2
% RSD 0.2 0.4 0.2 0.2

0.2

Robustness

Robustness was demonstrated by deliberately changing three critical parameters like mobile phase composition (± 10% mobile phase A), flow rate (± 10%) and column temperature (± 10%). The resulting    % RSD for Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox remained within specified limits. Mentioned in Table 17

Table 17: Robustness

Method Precision

% Bilastine % Lercanidipine % Rivaroxaban % Dolutegravir % Deferasirox
Change in Temperature 30° C 99.4 99.6 99.4 99.5

99.5

Change in Temperature 40° C

99.4 99.1 99.1 99.1 99.2
Flow rate 0.9 ml/min 99.5 98.9 98.9 98.8

98.9

Flow rate 1.1 ml/min

99.5 99.3 98.9 99.5 98.6
Change in Mobile Phase +10 % 99.5 98.9 99.3 100.9

98.6

Change in Mobile Phase -10 %

99.9 100.0 99.8 99.8 99.8

Solution Stability

Solution Stability is demonstrated by analysing sample solution at 100 % (100 µg/mL) for initial, 12 hrs & 24 hrs. No significant change observed. Mentioned in Table 18

 Table 18: Solution Stability

Method Precision

% Bilastine % Lercanidipine % Rivaroxaban % Dolutegravir % Deferasirox
Test solution   Initial 98.7 100.2 98.6 100.0

98.9

Test solution   After 12 hrs

98.9 99.1 98.9 100.4 99.2
Test solution   After 24 hrs 99.8 99.2 100.0 101.3

100.3

Table 19: Summary of HPLC method validation parameters as mentioned below

Parameters

Results
Bilastine  Lercanidipine  Rivaroxaban  Dolutegravir

Deferasirox

Method suitability

Peak resolution between Bilastine & Lercanidipine  ( ≥ 2.0)

NA 26.3 NA NA NA
Tailing Factor (≥ 2.0) 0.8 1.0 1.0 1.0

1.1

Theoretical Plates (≥ 1500)

38916 123395 92325 104076 150904
Linearity calibration range (ppm) 80 to 150 80 to 150 80 to 150 80 to 150

80 to 150

Correlation of coefficient (R2) (greater than 0.999)

0.9998 0.9998 0.9998 0.9997 0.9991
Precision % RSD (≤ 2.0) 0.3 0.4 0.8 0.7

0.5

Ruggedness % RSD (≤ 2.0)

0.2 0.4 0.2 0.2 0.2
Robustness % RSD (≤ 2.0)

Temperature (30 ° C)

0.5 0.3 0.3 0.3 0.3
Temperature (40 ° C) 0.3 0.1 0.2 0.2

0.1

Column 0.9 ml/min flow rate

0.05 0.1 0.2 0.1 0.1
Column 1.1 ml/min flow rate 1.2 0.1 0.2 0.8

0.2

Orthophosphoric acid in water 0.1 % v/v (+10 %)

0.4 0.6 0.5 0.5 0.2
Orthophosphoric acid in water 0.1 % v/v (-10 %) 0.2 0.2 0.9 0.2

0.2

Solution Stability (Initial, 12, 24 hrs) % RSD (≤ 2.0)

0.5 0.5 0.6 0.5

0.6

Conclusion

A novel RP-HPLC method was developed that enables robust and accurate simultaneous estimation and quantification of Bilastine, Lercanidipine, Rivaroxaban, Dolutegravir and Deferasirox. The new established RP-HPLC method was simple, selective, and cost-effective for routine analysis, continuous batch release and regulatory submission. The method achieved detection limits with linearity, method precision, accuracy, robustness and ruggedness within specified acceptance criteria. Thus, new developed quantification method offers valuable analytical tool in manufacturing processes and can be implemented to generate accurate and reliable results with sustainable approach.

Acknowledgement

The author wishes to thank Department of Chemistry Ramnarain Ruia Autonomous College and NSRL laboratory Department of chemistry St. Xavier’s College, Mumbai for providing unconditional analytical support to carry out this research study work.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The author(s) do not have any conflict of interest.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Authors’ Contributions

  • Harish Bhandarkar: data collection, data investigation characterization, method development, validation and manuscript drafting.
  • Vijaykumar Chavan: ideation, supervision, drafting, reviewing and editing.
  • Pralhad Rege: ideation, supervision, reviewing, drafting, and editing.

References 

  1. Çelebier, M.; Reçber, T.; Koçak, E.; Altinöz, S. RP-HPLC Method Development and Validation for Estimation of Rivaroxaban in Pharmaceutical Dosage Forms. Braz. J. Pharm. Sci. 2013, 49 (2), 359–366.
    CrossRef
  2. Holm, R.; Elder, D. P. Analytical Advances in Pharmaceutical Impurity Profiling. Eur. J. Pharm. Sci. 2016, 87, 118–135.
    CrossRef
  3. Cusato, J.; Allegra, S.; Silvia De Francia; Davide Massano; Antonio Giulio Piga; D’Avolio, A. Role of Pharmacogenetics on Deferasirox AUC and Efficacy. Pharmacogenomics 2016, 17 (6), 571–582.
    CrossRef
  4. Bhavar, G. B. High-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Method for Quantitative Estimation of Dolutegravir Sodium in Bulk Drug and Pharmaceutical Dosage Form. Sci. Pharm. 2016, 84 (2), 305–320.
    CrossRef
  5. Bonde, C.; Bonde, S.; Gawad, J. K. Application of Quality by Design for Development and Validation of RP-HPLC Method for Lercanidipine Hydrochloride. Asian J. Chem. 2017, 29 (12), 2785–2793.
    CrossRef
  6. Attimarad, M.; Venugopala, K. N.; Sreeharsha, N.; Chohan, M. S.; Shafi, S.; Nair, A. B.; Pottathil, S. A Rapid HPLC method for the concurrent determination of several antihypertensive drugs from binary and ternary formulations. Separations 2021, 8 (6), 86.
    CrossRef
  7. Din M, S. E.; F, I.; SH, S.; Aziz H, A. E. Spectrophotometric Methods for Simultaneous Determination of Rivaroxaban and Clopidogrel in Their Binary Mixture. Pharm. Anal. Acta.2017, 09 (01).
    CrossRef
  8. Mandake, G. R.; Patil, I. S.; Patil, O. A.; Nitalikar, M. M.; Mohite, S. K. UV Spectroscopy Analysis and Degradation Study of Rivaroxaban. Asian J. Res. Pharm. Sci. 2018, 8 (2), 57.
    CrossRef
  9. SK. Mastanamma, M.; Jyothi, J. A.; P. Saidulu, S.; M. Varalakshmi, V. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Lamivudine, Tenofovir Alafenamide and Dolutegravir Bulk and Their Combined Dosage Form. Pharm. Methods.2018, 9 (2), 49–55.
    CrossRef
  10. Malik, A.; Firke, S. D.; Patil, R. R.; Shirkhedkar, A. A.; Surana, S. J. Determination of Iron Chelating Agents by Analytical Methods: A Review. Critical Reviews in Analytical Chemistry 2019, 50 (3), 254–264.
    CrossRef
  11. Rathod, S. M.; Patel, P. U. Development and Validation of RP – HPLC Method for Estimation of Lamivudine and Dolutegravir Sodium in Synthetic Mixture. Res. J. Pharm. Technol. 2020, 13 (6), 2864–2864.
    CrossRef
  12. Sharma, S.; Hatware, K.; Bhadane, P.; Patil, K. Chemistry, Pharmacokinetics, Pharmacodynamics and Analytical Methods of Bilastine, a Histamine H1 Receptor Antagonist: An Update. Mini reviews in medicinal chemistry 2021, 21 (20), 3183–3190.
    CrossRef
  13. R Saravanan; T. Somanathan; D. Gavaskar; M. Tamilvanan. Analytical Method Development and Validation of Stability Indicating Assay Method of Analysis for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate Tablets Using High Performance Liquid Chromatography. Res. J. Pharm. Technol. 2021, 14 (5), 2434–2439.
    CrossRef
  14. Beltagi, A. M.; Lashin, I. A.; Essa, W. A.; Hathoot, A. A.; M. Abdel Azzem. Evolution and Effectiveness of HPLC Technique for Rapid Estimation of an Antiallergenic Agent Bilastine. Asian J. Pharm. Anal. 2021, 57–62.
    CrossRef
  15. Ettaboina,S.; Nakkala K.; Chathalingath, N. Development and Validation of Rapid RP-HPLC Method for Determination of Deferasirox in Bulk and Tablet Dosage Forms. Asian J. Pharm. Anal. 2022, 12 (2), 73–77.
    CrossRef
  16. Thakare B; Mittal, A.; Charde M; Umbarkar R; Kohle, N.; Chandra, P.; Kadam, M. Development and Validation of Stability-Indicating Assay UHPLC Method for Simultaneous Analysis of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate in Bulk and Pharmaceutical Formulation. Res. J. Pharm. Technol. 2022, 15 (9), 4061–4066.
    CrossRef
  17. Martini, P. R. R.; Dos Santos Porto, D.; Ribeiro Motta, P.; Bajerski, L.; Donadel Malesuik, M.; Soldateli Paim, C. Bilastine: Stability-Indicating a Method Using Environmentally Friendly by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). DAR. 2022, 6 (1), 13–20.
    CrossRef
  18. Jain, P.; Thota, A.; Saini, P. K.; Raghuvanshi, R. S. Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir. Critical Reviews in Analytical Chemistry 2022, 54 (2), 401–415.
    CrossRef
  19. Hajdys, J.; Piotr Fularski; Klaudia Leszto; Majchrowicz, G.; Stabrawa, M.; Ewelina Młynarska; Rysz, J.; Franczyk, B. New Insights into the Nephroprotective Potential of Lercanidipine. Int. J. Mol. Sci. 2023, 24 (18), 14048–14048.
    CrossRef
  20. Ajitha Azhakesan; Kishore Kumar Pasupuletti; Narendra Pentu. A Critical Review of Analytical Methods for Quantification of Rivaroxaban in Biological Samples and Pharmaceutical Formulations. J. Appl. Pharm. Sci. 2024, 15 (2).
    CrossRef
  21. Laddika Lakshmi Hari Sahitya; Dr. P. Uma Devi; Dr. P. V. Madhavi Latha. Method Development and Validation for the Simultaneous Estimation of Bilastine and Montelukast in Bulk and Pharmaceutical Dosage Forms by Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). J. Transl. Res. Life Sci.2025, 1 (5), 1–10.
    CrossRef
  22. Trivedi, R.; Suhagia, B. Development and Validation of Deferasirox-Related Substance Method in Solid Dosage Forms Using HPLC. Int. J. Appl. Pharm. 2025, 17 (2), 281–292.
    CrossRef
  23. Raju, M. D.; Palivela, P. K.; Rayinuthala, Y. A Reverse Phase High Performance Liquid Chromatography-Photo Diode Array Estimation of Probenecid and Sulopenem Etzadroxil in bulk and pharmaceutical dosage form and characterization of degradants by using liquid chromatography mass spectrometry. Int. J. Appl. Pharm 2026, 18 (1), 250–262.
    CrossRef
  24. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization (2003).
  25. ICH Validation of analytical procedures: Text and methodology Q2 (R1), International Conference on Harmonization (2005).
  26. ICH, Impurities in new drug substances Q3A (R2), International Conference on Harmonization (2006).
Article Publishing History
Received on: 20 Apr 2026
Accepted on: 27 Jun 2026

Article Review Details
Reviewed by: Dr. Purushotham
Second Review by: Dr. Naresh Batham
Final Approval by: Dr. Ravindra M Kumbhare


Share

ISSN Print: 0970-020X
ISSN Online: 2231-5039

Journal is Indexed in

Cabells Whitelist


Journal Archived in: